Anti-MOG; MOG Antibodies
Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies, CSF
Test
Aliases/Synonyms
Method
Cell-Based Indirect Immunofluorescence
Method Description
This specific and sensitive cell-based assay is based on transfected cells expressing the full-length human MOG as target antigen.
Report Includes
Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG)
Specimens
CSF
Clinical Utility
Many cases of Neuromyelitis Optica-spectrum disorders (NMOSD) are misdiagnosed as Multiple Sclerosis. As correct diagnosis is critical for prognosis, optimal treatment and prediction of relapse, initial testing for both Aquaporin 4 (AQP4) Antibodies and Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies is strongly recommended for new cases of NMOSD – see separate test listings. AQP4 antibodies are detected in about 80% of patients with NMO. Of these seronegative AQP-4 cases 7% will harbor MOG antibodies. Patients very rarely harbour both antibodies.
Test Location
St. Joseph's Hospital, 30 The Queensway, Toronto ON M6R 1B5
Test Version
15-Nov-2023
Specimen
Specimens
CSF
Sample Volume
1 mL
Minimum Volume
0.5 mL
Collection & Handling
Handling Information
Store and send frozen.
Stability
Ambient | 6 hours |
---|---|
Refrigerated | 14 days |
Frozen | 60 days |
Test Version
15-Nov-2023
Performance / Interpretation
Method
Cell-Based Indirect Immunofluorescence
Method Description
This specific and sensitive cell-based assay is based on transfected cells expressing the full-length human MOG as target antigen.
Turnaround Time
9 days
Results
Name | Units | Reference Range | Conversion Factor | |
---|---|---|---|---|
Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG) |
|
|||
Results of 1+ to 4+ indicate the presence of this autoantibody in increasing titers
|
Test Location
St. Joseph's Hospital, 30 The Queensway, Toronto ON M6R 1B5
Test Version
15-Nov-2023
Interface / Setup
HL7 Interface Codes
Order Code | Result Codes | Units |
---|---|---|
MOG CSF | 62784Anti MOG (CSF) |
Test Version
15-Nov-2023